glucagon

Phase 1/2Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Post-bariatric Hypoglycemia

Conditions

Post-bariatric Hypoglycemia

Trial Timeline

Sep 19, 2017 → Aug 22, 2018

NCT ID

NCT03255629

About glucagon

glucagon is a phase 1/2 stage product being developed by Xeris Pharmaceuticals for Post-bariatric Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03255629. Target conditions include Post-bariatric Hypoglycemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03255629	Phase 1/2	Completed	Sep 19, 2017	Aug 22, 2018	Post-bariatric Hypoglycemia
NCT03091673	Phase 3	Completed	Mar 27, 2017	Sep 27, 2017	Diabetes Mellitus, Type 1
NCT02937558	Phase 2	Completed	Oct 1, 2016	Oct 1, 2018	Congenital Hyperinsulinism
NCT02423980	Phase 2	Completed	Apr 1, 2015	Jun 1, 2015	Hypoglycemia

Competing Products

1 competing product in Post-bariatric Hypoglycemia

See all competitors

Product	Company	Stage	Hype Score
Pasireotide Diaspartate	Recordati	Phase 2	49

Other Products from Xeris Pharmaceuticals

G-Pen (glucagon injection) + Lilly Glucagon (glucagon injection [rDNA origin])Phase 3

G-Pen + Novo GlucagonPhase 3

G-Pen + Lilly GlucagonPhase 3

GlucagonPhase 3

Glucagon RTUPhase 2